Erratum: Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial (The Lancet (2018) 392(10143) (222–231) (S0140673618313631) (10.1016/S0140-6736(18)31363-1));Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

The Lancet

Volumn 392, Issue 10143, 2018, Pages 222-231

  Wallace, Daniel J ^a   Furie, Richard A ^b   Tanaka, Yoshiya ^c   Kalunian, Kenneth C ^d   Mosca, Marta ^e   Petri, Michelle A ^f   Dörner, Thomas ^g   Cardiel, Mario H ^h   Bruce, Ian N ⁱ   Gomez, Elisa ^j   Carmack, Tara ^j   DeLozier, Amy M ^j   Janes, Jonathan M ^j   Linnik, Matthew D ^j   de Bono, Stephanie ^j   Silk, Maria E ^j   Hoffman, Robert W ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PISA   (Italy)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h Centro de Investigacion Clinica de Morelia   (Mexico)

ⁱ UNIVERSITY OF MANCHESTER   (United Kingdom)

^j ELI LILLY AND COMPANY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; BARICITINIB; CHOLESTEROL; CORTICOSTEROID; CREATINE KINASE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLATE MOFETIL; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; TRIACYLGLYCEROL; AZETIDINE DERIVATIVE; JANUS KINASE INHIBITOR; SULFONAMIDE;

ADULT; ARTHRITIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEMOGLOBIN DETERMINATION; HERPES ZOSTER; HUMAN; INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUTROPHIL COUNT; PHASE 2 CLINICAL TRIAL; PLATELET COUNT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; BLOOD; CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; ARTHRITIS; AZETIDINES; CHOLESTEROL; CHOLESTEROL, HDL; CREATINE KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXANTHEMA; FEMALE; HUMANS; INFECTION; JANUS KINASE INHIBITORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PLATELET COUNT; SULFONAMIDES;

EID: 85050110746     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)31741-0     Document Type: Erratum

References (28)

1. Tsokos, GC, Lo, MS, Costa Reis, P, Sullivan, KE, New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol 12 (2016), 716–730.
2. Wahren-Herlenius, M, Dorner, T, Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 382 (2013), 819–831.
3. Schwartz, DM, Kanno, Y, Villarino, A, Ward, M, Gadina, M, O'Shea, JJ, JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 16 (2017), 843–862.
4. Hoffman, RW, Merrill, JT, Alarcon-Riquelme, MM, et al. Gene expression and pharmacodynamic changes in 1,760 systemic lupus erythematosus patients from two phase III trials of BAFF blockade with tabalumab. Arthritis Rheumatol 69 (2017), 643–654.
5. Fridman, JS, Scherle, PA, Collins, R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 184 (2010), 5298–5307.
6. Tan, EM, Cohen, AS, Fries, JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25 (1982), 1271–1277.
7. Hochberg, MC, Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 40, 1997, 1725.
8. Petri, M, Orbai, AM, Alarcon, GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64 (2012), 2677–2686.
9. Genovese, MC, Kremer, J, Zamani, O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374 (2016), 1243–1252.
10. Dougados, M, van der Heijde, D, Chen, YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 76 (2017), 88–95.
11. Fleischmann, R, Schiff, M, van der Heijde, D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheumatol 69 (2017), 506–517.
12. Taylor, PC, Keystone, EC, van der Heijde, D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376 (2017), 652–662.
13. Guttman-Yassky, E, Silverberg, JI, Nemoto, O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol, 2018 published online Feb 1. DOI:10.1016/j.jaad.2018.01.018.
14. Papp, KA, Menter, MA, Raman, M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol 174 (2016), 1266–1276.
15. Manzi, S, Sanchez-Guerrero, J, Merrill, JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 71 (2012), 1833–1838.
16. Kalunian, KC, Urowitz, MB, Isenberg, D, et al. Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. Rheumatology (Oxford) 57 (2018), 125–133.
17. Urowitz, M, Gladman, DD, Ibanez, D, et al. Changes in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 66 (2014), 1374–1379.
18. Urowitz, MB, Gladman, DD, Ibanez, D, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken) 64 (2012), 132–137.
19. Jolly, M, Pickard, AS, Block, JA, et al. Disease-specific patient reported outcome tools for systemic lupus erythematosus. Semin Arthritis Rheum 42 (2012), 56–65.
20. Moorthy, LN, Baldino, ME, Kurra, V, et al. Relationship between health-related quality of life, disease activity and disease damage in a prospective international multicenter cohort of childhood onset systemic lupus erythematosus patients. Lupus 26 (2017), 255–265.
21. Furie, RA, Petri, MA, Wallace, DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 61 (2009), 1143–1151.
22. MacDonald, KPA, Betts, BC, Couriel, D, Emerging therapeutics for the control of chronic graft-versus-host disease. Biol Blood Marrow Transplant 24 (2018), 19–26.
23. GlaxoSmithKline. Belimumab prescribing information. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Benlysta/pdf/BENLYSTA-PI-MG-IFU-COMBINED.PDF, 2017. (Accessed 31 May 2018)
24. Wallace, DJ, Kalunian, K, Petri, MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 73 (2014), 183–190.
25. Furie, R, Khamashta, M, Merrill, JT, et al. Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 69 (2017), 376–386.
26. Merrill, JT, Manzi, S, Aranow, C, et al. Lupus community panel proposals for optimising clinical trials: 2018. Lupus Sci Med, 5, 2018, e000258.
27. Yurkovich, M, Vostretsova, K, Chen, W, Avina-Zubieta, JA, Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res (Hoboken) 66 (2014), 608–616.
28. Thong, B, Olsen, NJ, Systemic lupus erythematosus diagnosis and management. Rheumatology (Oxford) 56:suppl 1 (2017), i3–i13.